Caba stock forecast 2025 for 2025

For 2025, many traders project "CABA stock forecast" levels supported by historical volume spikes and biotech ETF performance. If the industry maintains its 12% CAGR, market consensus suggests price resistance near $23, assuming no major delays in product commercialization. Explore Cabaletta Bio's Fair Values from the Community and select yours Cabaletta Bio (CABA) , with a market cap of $91.4 million, is a clinical-stage biotechnology company that has been developing novel cell therapies to treat autoimmune diseases. Its lead program, CABA-201 , has shown promising early results in multiple Phase 1/2 trials aimed at conditions such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and myositis. Market technicals shaping "CABA stock forecast 2025" reveal a tightening Bollinger Band pattern, often preceding a breakout. Downside risk remains if funding rounds dilute share value, but upside potential is noted if catalysts align.